Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Imiquimod
Drug ID BADD_D01142
Description Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. Imiquimod does not cure warts, and new warts may appear during treatment. Imiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and control wart production. Miquimod is also used to treat a skin condition of the face and scalp called actinic keratoses and certain types of skin cancer called superficial basal cell carcinoma.
Indications and Usage For the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults. Also indicated for the treatment of external genital and perianal warts/condyloma acuminata in individuals 12 years old and above.
Marketing Status Prescription; Discontinued
ATC Code D06BB10
DrugBank ID DB00724
KEGG ID D02500
MeSH ID D000077271
PubChem ID 57469
TTD Drug ID D06CTE
NDC Product Code 22365-121; 51927-0168; 66039-829; 0395-8244; 0093-3133; 63629-8818; 64552-4008; 62147-0087; 51672-4145; 99207-270; 62350-0077; 99207-276; 68462-536; 62147-0072; 45802-368; 68682-272; 99207-260; 72189-084; 71052-160; 99207-271; 0168-0432; 51552-1538; 58175-0397; 11517-270; 72643-006; 11517-275; 51927-4898; 51672-4174; 11517-262
Synonyms Imiquimod | 1-Isobutyl-1H-imidazo(4,5-c)quinolin-4-amine | S 26308 | S-26308 | R 837 | R-837 | R837 | Zyclara | Aldara
Chemical Information
Molecular Formula C14H16N4
CAS Registry Number 99011-02-6
SMILES CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Gastrointestinal pain07.01.05.005--
Genital candidiasis21.10.03.001; 11.03.03.002--Not Available
Gout15.01.06.001; 14.09.01.001--Not Available
Haemoglobin13.01.05.018--Not Available
Haemoglobin decreased13.01.05.0030.002317%Not Available
Headache17.14.01.0010.015062%
Henoch-Schonlein purpura01.01.04.001; 24.07.06.003; 23.06.01.002; 10.02.02.004--Not Available
Hepatic function abnormal09.01.02.001--Not Available
Hernia08.01.04.001--Not Available
Herpes simplex23.09.03.001; 11.05.02.001--Not Available
Herpes zoster11.05.02.003; 23.09.03.0020.003476%
Hyperaesthesia17.02.06.004--Not Available
Hypercholesterolaemia14.08.01.001--Not Available
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hyperkeratosis23.01.01.0010.005793%
Hypersensitivity10.01.03.0030.003476%
Hypertension24.08.02.001--
Hypertrophic scar23.01.03.003--Not Available
Hyponatraemia14.05.04.0020.002317%
Immobile26.01.01.002--Not Available
Immune system disorder10.02.01.001--Not Available
Infection11.01.08.0020.001511%Not Available
Influenza22.07.02.001; 11.05.03.001--Not Available
Influenza like illness08.01.03.0100.015062%
Injury12.01.08.004--Not Available
Insomnia19.02.01.002; 17.15.03.0020.009269%
Instillation site pain12.07.01.008; 08.02.01.008--Not Available
Irritability19.04.02.013; 08.01.03.011--
Kaposi's sarcoma16.33.02.001; 11.05.17.0010.002317%Not Available
Laceration23.03.11.004; 12.01.06.0060.002317%Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 12 Pages